Cinnarizin Sopharma 50 tablets 25mg Сinnarizine Циннаризин Meniere disease

Cinnarizin Indications

Symptomatic treatment of labyrinthine and vestibular disorders of vascular origin, Meniere's disease.
Prevention kinetoses.

Supportive treatment for symptoms of labyrinthine disorders including dizziness, nausea, vomiting, tinnitus and nystagmus.

- Prevention of motion sickness.

- Migraine prevention.

- Supportive treatment for symptoms of cerebrovascular origin, including dizziness, ringing in the ears (tinnitus), vascular headache, irritability, memory loss and inability to concentrate.

- Supportive treatment for symptoms of peripheral vascular disorders, including Raynaud's disease, acrocyanosis, intermittent claudication, trophic disorders and varicose ulcers, paresthesia, nocturnal cramps in the limbs, coldness in the limbs.

Dosage & Administration

Adults and children from 12 years. The tablets are taken orally after a meal, drinking plenty of water.
Symptomatic treatment of labyrinthine and vestibular disorders of vascular origin, Meniere's disease. The daily dose is 75 mg (3 tablets), take 1 tablet, 3 times a day.

Prevention kinetoses. Take 1 tablet 2 hours before heading to the road and 1 tablet every 8 hours later in a travel.
Do not exceed the recommended dose.

The maximum daily dose for adults is 225 mg (9 tablets).
The effectiveness of treatment depends on the individual mode dose and sufficiently long duration of treatment.

Contradictions

Hypersensitivity to the active substance or to any component of the drug.

The drug is contraindicated during pregnancy and lactation.

Do not appy to children under the age of 12 years.